BridgeBio Pharma, Inc. vs Johnson & Johnson
BBIO vs JNJ — side-by-side comparison from reported financials. BBIO leads 2, JNJ leads 6 of 8 comparable metrics.
BridgeBio Pharma, Inc.
BBIO · Healthcare
$65.35+0.48%Strained
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | BBIO | JNJ |
|---|---|---|
| Price | $65.35 | $261.79 |
| Market cap | $12.8B | $631B |
| Revenue (TTM) | $713M | $97.9B |
| Revenue growth | +86.3% | +5.6% |
| Net margin | -97.0% | 21.5% |
| Free cash flow | -$435M | $22.2B |
| Net cash (debt) | ($1.26B) | ($27.8B) |
| 1-year price return | +19.3% | +37.0% |
| P/E | — | 29.9 |
| P/E vs own history (cheap-side %) | — | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | -207% | 26% |
| Altman Z-score | -2.72 | — |
| CV checks passed | 3 of 9 | 10 of 9 |
| Employees | 839 | 140,800 |
Full résumé-style profiles: BBIO CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.